E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 960-971

  Watanabe, Nao Aki ^a   Miyazaki, Mamiko ^a   Horii, Takaaki ^a   Sagane, Koji ^a   Tsukahara, Kappei ^a   Hata, Katsura ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; E1210; GLYCOSYLPHOSPHATIDYLINOSITOL; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INOSITOL; POLYSTYRENE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ACYLATION; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CELL SURFACE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME MECHANISM; FUNGUS GROWTH; HUMAN; IC 50; LIPOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING;

ACYLATION; AMINOPYRIDINES; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; HYPHAE; INOSITOL; ISOXAZOLES; VIRULENCE; VIRULENCE FACTORS;

EID: 84856073587     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00731-11     Document Type: Article

References (70)

1. Abe S, Satoh T, Tokuda Y, Tansho S, Yamaguchi H. 1994. A rapid colorimetric assay for determination of leukocyte-mediated inhibition of mycelial growth of Candida albicans. Microbiol. Immunol. 38:385-388.
2. Albrecht A, et al. 2006. Glycosylphosphatidylinositol-anchored proteases of Candida albicans target proteins necessary for both cellular processes and host-pathogen interactions. J. Biol. Chem. 281:688-694.
3. Andes D, et al. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-6031. (Pubitemid 39303717)
4. Bachmann SP, et al. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596. (Pubitemid 35192931)
5. Brayman TG, Wilks JW. 2003. Sensitive assay for antifungal activity of glucan synthase inhibitors that uses germ tube formation in Candida albicans as an end point. Antimicrob. Agents Chemother. 47:3305-3310. (Pubitemid 37229593)
6. Brown DH, Jr., Giusani AD, Chen X, Kumamoto CA. 1999. Filamentous growth of Candida albicans in response to physical environmental cues and its regulation by the unique CZF1 gene. Mol. Microbiol. 34:651-662.
7. Chaffin WL. 2008. Candida albicans cell wall proteins. Microbiol. Mol. Biol. Rev. 72:495-544.
8. Clinical Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard-seventh edition, M07-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard-third edition, M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Costello LC, Orlean P. 1992. Inositol acylation of a potential glycosyl phosphoinositol anchor precursor from yeast requires acyl coenzyme A. J. Biol. Chem. 267:8599-8603.
11. Davis DA, Bruno VM, Loza L, Filler SG, Mitchell AP. 2002. Candida albicans Mds3p, a conserved regulator of pH responses and virulence identified through insertion mutagenesis. Genetics 162:1573-1581. (Pubitemid 36114647)
12. Denning DW, Hope WW. 2010. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195-204.
13. Epp E, et al. 2010. Forward genetics in Candida albicans that reveals the Arp2/3 complex is required for hyphal formation, but not endocytosis. Mol. Microbiol. 75:1182-1198.
14. Ferguson MAJ, et al. 1999. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim. Biophys. Acta 1455:327-340. (Pubitemid 29435998)
15. Fu Y, et al. 2002. Candida albicans Als1p: an adhesion that is a downstream effector of the EFG1 filamentation pathway. Mol. Microbiol. 44:61-72. (Pubitemid 34429765)
16. Fu Y, Luo G, Spellberg BJ, Edwards JE, Jr., Ibrahim S. 2008. Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans. Eukaryot. Cell 7:483-492. (Pubitemid 351959676)
17. Grimme SJ, Colussi PA, Taron CH, Orlean P. 2004. Deficiencies in the essential Smp3 mannosyltransferase block glycosylphosphatidylinositol assembly and lead to defects in growth and cell wall biogenesis in Candida albicans. Microbiology 150:3115-3128. (Pubitemid 39406184)
18. Hashash R, et al. 2011. Characterisation of Pga1, a putative Candida albicans cell wall protein necessary for proper adhesion and biofilm formation. Mycoses 54:491-500.
19. Hata K, et al. 2011. Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis. 240 Antimicrob. Agents Chemother. 55:4543-4551.
20. Hawser S, Francolini M, Islam K. 1996. The effects of antifungal agents on the morphogenetic transformation by Candida albicans in vitro. J. Antimicrob. Chemother. 38:579-587. (Pubitemid 26390399)
21. Hernáez et al. 2010. Identification of Candida albicans exposed surface proteins in vivo by a rapid proteomic approach. J. Proteomics 73:1404-1409.
22. Hong Y, et al. 1999. Pig-n, a mammalian homologue of yeast Mcd4p, involved in transferring phosphoethanolamine to the first mannose of the glycosylphosphatidylinositol. J. Biol. Chem. 274:35099-35106. (Pubitemid 129509564)
23. Hoyer LL. 2001. The ALS gene family of Candida albicans. Trends Microbiol. 9:176-180. (Pubitemid 32247378)
24. Jacobson MJ, Steckelberg KE, Piper KE, Steckelberg JM, Patel R. 2009. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob. Agents Chemother. 53:2638-2639.
25. Kapteyn JC, et al. 2000. The cell wall architecture of Candida albicans wild-type cells and cell wall-defective mutants. Mol. Microbiol. 35:601-611. (Pubitemid 30085277)
26. Kinoshita T, Fujita M. 2009. Overview of GPI biosynthesis, p. 1-30. In Menon AK, Kinoshita T, Orlean P, and Tamanoi F (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins. Academic Press, London, United Kingdom.
27. Kollar R, et al. 1997. Architecture of the yeast cell wall. β(1→6)-Glucan interconnects mannoprotein, beta(1→3)-glucan, and chitin. J. Biol. Chem. 272:17762-17775. (Pubitemid 27311216)
28. Lee KL, Buckley HR, Campbell CC. 1975. An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida albicans. Sabouraudia 13:148-153.
29. Leidich SD, Drapp DA, Orlean P. 1994. A conditionally lethal yeast mutant blocked at the first step in glycosylphosphatidylinositol anchor synthesis. J. Biol. Chem. 269:10193-10196. (Pubitemid 24198203)
30. Li F, et al. 2007. Eap1p, an adhesion that mediated Candida albicans biofilm formation in vitro and in vivo. Eukaryot. Cell 6:931-939. (Pubitemid 46983293)
31. Liu H, Köhler J, Fink GR. 1994. Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 266:1723-1726.
32. Martchenko M, Alarco AM, Harcus D, Whiteway M. 2004. Superoxide dismutases in Candida albicans: transcriptional regulation and functional characterization of the hyphal-induced SOD5 gene. Mol. Biol. Cell 15:456-467. (Pubitemid 38146465)
33. Messer SA, Jones RN, Fritsche TR. 2006. International surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY antimicrobial surveillance program (2003). J. Clin. Microbiol. 44:1782-1787. (Pubitemid 43726269)
34. Miyazaki M, et al. 2011. In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds. Antimicrob. Agent Chemother. 55:4652-4658.
35. Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW. 2005. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl. Environ. Microbiol. 71:4938-4940. (Pubitemid 41129562)
36. Murakami Y, et al. 2003. PIG-W is critical for inositol acylation but not for flipping of glycosylphosphatidylinositol-anchor. Mol. Biol. Cell 14:4285-4295. (Pubitemid 37186328)
37. Nagamune K, et al. 2000. Critical roles of glycosylphosphatidylinositol for Trypanosoma brucei. Proc. Natl. Sci. U. S. A. 97:10336-10341.
38. Nakamoto K, et al. 2010. Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives. Bioorg. Med. Chem. Lett. 20:4624-4626.
39. Neofytos D, et al. 2009. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin. Infect. Dis. 48:265-273.
40. Nobile CJ, Nett JE, Andes DR, Mitchell AP. 2006. Function of Candida albicans adhesion Hwp1 in biofilm formation. Eukaryot. Cell 5:1604-1610. (Pubitemid 44622591)
41. Nobile CJ, et al. 2008. Complementary adhesion function in C. albicans biofilm formation. Curr. Biol. 18:1017-1024.
42. Ogawa-Mitsuhashi K, Sagane K, Kuromitsu J, Takagi H, Tsukahara K. 2009. MPR1 as a novel selection marker in Saccharomyces cerevisiae. Yeast 26:587-589.
43. Orlean P, Menon AK. 2007. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids. J. Lipid Res. 48:993-1011. (Pubitemid 46708667)
44. Pfaller MA, et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
45. Pfaller MA, et al. 2010. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J. Clin. Microbiol. 48:1366-1377.
46. Pittet M, Conzelmann A. 2007. Biosynthesis and function of GPI proteins in the yeast Saccharomyces cerevisiae. Biochim. Biophys. Acta 1771:405-420. (Pubitemid 46428606)
47. Presterl E, Daxböck F, Grainger W, Willinger B. 2007. Changing pattern of candidaemia 2001-2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. Clin. Microbiol. Infect. 13:1072-1076. (Pubitemid 47543107)
48. Ramage G, Walle KV, Wickes BL, López-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. (Pubitemid 32801898)
49. Ramage G, Saville SP, Thomas DP, López-Ribot JL. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638. (Pubitemid 40600417)
50. Richard M, et al. 2002. Complete glycosylphosphatidylinositol anchors are required in Candida albicans for full morphogenesis, virulence and resistance to macrophages. Mol. Microbiol. 44:841-853. (Pubitemid 34526593)
51. Richard ML, Plaine A. 2007. Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans. Eukaryot. Cell 6:119-133.
52. Santos de Macedo C, Shams-Eldin H, Smith TK, Schwarz RT, Azzouz N. 2003. Inhibitors of glycosyl-phosphatidylinositol anchor biosynthesis. Biochimie. 85:465-472. (Pubitemid 36626017)
53. Seidler M, Salvenmoser S, Müller FMC. 2006. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int. J. Antimicrob. Agents 28:568-573. (Pubitemid 44779180)
54. Seidler MJ, Salvenmoser S, Müller FMC. 2008. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelial cells. Antimicrob. Agents Chemother. 52:4130-4136.
55. Sheppard DC, et al. 2004. Functional and structural diversity in the Als protein family of Candida albicans. J. Biol. Chem. 279:30480-30489. (Pubitemid 38937978)
56. Smith TK, Kimmel J, Azzouz A, Shams-Eldin H, Schwarz RT. 2007. The role of inositol acylation and inositol deacylation in the Toxoplasma gondii glycosylphosphatidylinositol biosynthetic pathway. J. Biol. Chem. 282:32032-32042. (Pubitemid 350106437)
57. Smith TK. 2009. Inhibitors of GPI biosynthesis, P. 247-267. In Menon AK, Kinoshita T, Orlean P, and Tamanoi F (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins, Academic Press, London, United Kingdom.
58. Sütterlin C, et al. 1997. Identification of a species-specific inhibitor of glycosylphosphatidylinositol synthesis. EMBO J. 16:6374-6383. (Pubitemid 27483264)
59. 2: synthesis of a (2-aminopyridin-3-yl)isoxazole derivative and its antifungal activity. Chem. Lett. 39:1033-1035.
60. Theiss S, et al. 2006. Inactivation of the phospholipase B gene PLB5 in wild-type Candida albicans reduces cell-associated phospholipase A2 activity and attenuates virulence. Int. J. Med. Microbiol. 296:405-420. (Pubitemid 44354304)
61. Toenjes KA, et al. 2005. Small-Molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 49:963-972. (Pubitemid 40327711)
62. Tronchin G, Bouchara J-P, Robert R, Senet J-M. 1988. Adherence of Candida albicans germ tubes to plastic: ultrastructural and molecular studies of fibrillar adhesions. Infect. Immun. 56:1987-1993.
63. Tsukahara K, et al. 2003. Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly. Mol. Microbiol. 48:1029-1042. (Pubitemid 36628267)
64. Umemura M, et al. 2003. GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast. J. Biol. Chem. 278:23639-23647. (Pubitemid 36830186)
65. Van 't Wout JW, et al. 1990. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J. Antimicrob. Chemother. 25:803-811. (Pubitemid 20183041)
66. Verweij PE, Mellado E, Melchers WJG. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
67. Victoria GS, Kumar P, Komath SS. 2010. The Candida albicans homologue of PIG-P, CaGpi19p: gene dosage and role in growth and filamentation. Microbiology 156:3041-3051.
68. Warnock DW. 2007. Trends in the epidemiology of invasive fungal infections. Jpn. J. Med. Mycol. 48:1-12. (Pubitemid 46280129)
69. Xu D, et al. 2007. Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. PLoS Pathog. 3:e92.
70. Yoko-o T, Jigami Y. 2009. Inositol acylation/deacylation, p. 65-90. In Menon AK, Kinoshita T, Orlean P, and Tamanoi F (ed.), The enzymes, vol. XXVI. Glycosylphosphatidylinositol (GPI) anchoring of proteins. Academic Press, London, United Kingdom.